Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||01/06/2018|
|Rapid review completed||22/06/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||22/06/2018|
|Pre-submission consultation with Applicant||31/07/2018|
|Submission received from Applicant||14/09/2018|
|Preliminary review sent to Applicant||13/11/2018|
|Preliminary review II sent to Applicant||27/11/2018|
|NCPE assessment re-commenced||03/12/2018|
|Factual accuracy sent to Applicant||11/01/2019|
|NCPE assessment re-commenced||18/01/2019|
|NCPE assessment completed||31/01/2019|
|NCPE assessment outcome||The NCPE recommends that
pertuzumab (in combination with trastuzumab and chemotherapy) for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence (defined here as patients with node-positive or hormone receptor-negative disease), not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to thecriteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.